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Background: Bacteria such as Staphylococcus aureus induce myocardial dysfunction in vivo. To rectify conflicting
evidence about the role of TLR2 signaling and cardiac dysfunction, we hypothesized that the specific TLR2 agonist
purified lipoteichoic acid (LTA) from S. aureus contributes to cardiac dysfunction in vitro and in vivo.
Methods: Wildtype (WT-) and TLR2-deficient (TLR2-D) mice were challenged with LTA and in comparison with
equivalent doses of lipopolysaccharide (LPS) and CpG-oligodeoxynucleotide (CpG-ODN). TLR2-expression, NFκB as
well as cytokine response were determined. Sarcomere shortening of isolated cardiomyocytes was analyzed in vitro
and cardiac function in vivo after stimulation with LTA.
Results: LTA induced up-regulation of TLR2 mRNA, activation of NFκB and cytokine expression within 2–6 h in WT-,
but not in TLR2-D hearts. Cytokines were also elevated in the serum. LPS and CpG-ODN induced a more severe
cardiac inflammation. In vitro incubation of cardiomyocytes with LTA reduced sarcomere shortening via NO at
stimulation frequencies ≤ 8 Hz only in WT cells. However, hemodynamic parameters in vivo were not affected by
LTA challenge.
Conclusions: LTA induced cardiac inflammation was relatively weak and sarcomere shortening was reduced only
below physiological heart rates. This may explain the apparent contradiction between the in vivo and in vitro LTA
effects.
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Impairment of cardiac function independently increases
mortality during septic shock [1]. Experimental studies
show a similar pattern of cardiac dysfunction in Gram-
negative and Gram-positive sepsis [2]. Epidemiological
data indicate increasing incidence of Gram-positive sepsis
[3,4] pointing to a growing need to further elucidate
mechanisms underlying cardiac dysfunction during Gram-
positive sepsis.
An increase in tumor necrosis factor (TNF)-α and
interleukin (IL)-1β contributes to cardiac dysfunction
during sepsis in humans [5-7] and has been directly* Correspondence: Pascal.Knuefermann@ukb.uni-bonn.de
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reproduction in any medium, provided the orlinked to Toll-like receptor (TLR) signaling. Of the
eleven human TLRs described so far [8] TLR2 binds
wall components from Gram-positive bacteria thereby
inducing an inflammatory response. However, controversy
still exists about the exact role of TLR2-dependent inflam-
mation and the onset of cardiac dysfunction. On the one
hand heat-inactivated Staphylococcus aureus (S. aureus)
has been shown to induce cardiac TNF-α, IL-1β, and nitric
oxide (NO) [9] the latter being another pivotal stepstone
for the development of septic cardiac dysfunction and
failure. More importantly, TLR2-deficient mice were
protected against S. aureus-induced myocardial dysfunction
and cytokine production [9]. However, recent studies of
Plitas et al. and of our group have revealed a pivotal role
of CD14/TLR9 signaling in polymicrobial sepsis [10,11]. In
addition, TLR2 signaling appears to be of minor importance
in vascular inflammation during polymicrobial sepsis [11].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of TLR2-dependent inflammation and its role in the
development of cardiac dysfunction.
Therefore, we hypothesized that the bacterial cell wall
component lipoteichoic acid (LTA), a specific TLR2 ligand,
contributes to cardiac dysfunction. To test this hypothesis
we applied highly purified LTA and monitored mediators
of inflammation in the heart and serum, as well as physio-




Male 12–14 week old C57BL/6 wild-type (WT) mice were
purchased from Charles River (Charles River, Sulzfeld,
Germany). TLR2-deficient (TLR2-D) mice were kindly
provided by Prof. Shizuo Akira (Osaka University) and
back-crossed onto a C57BL/6 background. Mice received
water ad libitum, standard rodent chow and were housed
in pathogen-free cages. The investigation conformed to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996), and animal proce-
dures were approved by the local committee for animal
care (Bezirksregierung Köln, Cologne, Germany).
Study design
The study was conducted in four sets of experiments:
A. Cardiac and systemic inflammation: 0, 2, 4, and 6 h
after i.p. injection of LTA (15 mg/kg) pattern
recognition receptors (PRRs) and inflammatory
mediators were monitored in the hearts and in the
serum of WT and TLR2-D mice (Figures 1, 2, 3).
B. Comparison of different TLR ligands: 4 h after i.p.
injection of LTA (15 mg/kg), LPS (20 mg/kg) or
CpG-ODN 1668-thioate (1 nmol/g) mRNA expression
of PRRs, inflammatory cytokines and iNOS was
analyzed in the hearts of WT mice (Figure 4).
C. In vitro cardiac function: Starting at 1 up to 8 h after
incubation with LTA (10 μg/ml) sarcomere
shortening was recorded in isolated cardiomyocytes
from WT and TLR2-D mice. Additionally, another
subgroup of WT cardiomyocytes was incubated with
LTA (10 μg/ml) for 6 h and the iNOS inhibitor
S-methylisothiourea (SMT, 100 μM) was added
after 5 h (Figure 5).
D. In vivo cardiovascular function: 4 h after stimulation
with different concentrations of LTA (15 and 30 mg/kg)
hemodynamic parameters were monitored with a
pressure-volume catheter in WT mice. For further
corroboration, control experiments involving
systemic invasive blood pressure measurements
were performed in another study in WT animalswith a pressure-catheter 6 h after stimulation with
different concentrations of LTA (15, 30 and 50 mg/kg)
(Figure 6).
Stimulation protocol
Lipoteichoic acid (charge MGM5-10) was prepared as
described previously [12]. Lipopolysaccharide (LPS) con-
tamination was determined to be less than 1 EU/mg as
determined by LIMULUS amoebocyte lysate assay (Charles
River, Charleston, SC). Additionally, commercially available
and highly purified LTA was purchased from Sigma-
Aldrich (Sigma-Aldrich, Munich, Germany). These LTAs
were applied in experiments of type A)-D).
In experiment type B) LPS (LPS; E. coli 0:111, Sigma
Aldrich) and endotoxin-free cytidine triphosphate oligode-
soxynucleotide (CpG-ODN; 1668-thioate; Tib-MolBiol,
Berlin, Germany) [13] were applied alternatively. Purified
LTA (15 mg/kg), LPS (20 mg/kg) and CpG-ODN (1 nmol/g
1668 thioate) were dissolved in endotoxin-free water.
Previously, in a fibroblast assay we demonstrated that
the chosen concentrations of LTA (15 mg/kg i.p.), LPS
(20 mg/kg i.p.) and CpG-ODN (1 nmol/g i.p.) are equipo-
tent with respect to TNF-activity induction [14].
Furthermore, LTA was tested in higher concentrations
(30 mg/kg ≈ 600 μg/mouse; 50 mg/kg ≈ 1000 μg/mouse)
for hemodynamic measurements in experiment type D). In
all experiments each TLR-ligand was injected i.p. according
to the study design before the animals were sacrificed.
EMSA
Myocardial protein extracts were prepared with NE-PER®
Nuclear and Cytoplasmic Extraction Reagents (Perbio
Science, Bonn, Germany), as previously published [13].
Nuclear factor 'kappa-light-chain-enhancer’ of activated
B-cell (NFκB) oligonucleotides were end-labeled with
Gamma 32P [γ-32P] adenosine triphosphate (ATP). Binding
reactions (25 μl total) were performed with nuclear extracts.
The specificity of DNA-protein binding was determined
by cold chase (cc) analysis and supershift assays. Nuclear
extracts were incubated with 2 mg of polyclonal anti-p50
(sc-114x) or anti-p65 (sc-109x) antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Deoxyribonucleic acid -
protein complexes were electrophoresed; gels were dried,
exposed overnight and scanned with a phosphoimager.
mRNA isolation and RT-qPCR
Total ribonucleic acid (RNA) from whole hearts was
isolated with the guanidinum thiocyanate method [6].
First-strand cDNA was synthesized according to the
manufacturer’s protocol using the High-Capacity cDNA
transcription kit (Applied Biosystems, Darmstadt, Germany)
with random hexameric primers. Relative RT-qPCR was
performed and analyzed with cDNA (diluted 1:10) on an
ABI Prism 7900 Sequence Detection System and SDS2.2
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Figure 1 Time course of inflammatory parameters in hearts of WT- and TLR2-D mice after LTA challenge (15 mg/kg, i.p). A: RT-qPCR of
TLR2. Peak expression was detected after 4 h. (*p < 0.05; n = 6; mean ± SEM). B: NFκB-DNA binding activity following LTA stimulation (EMSA).
Lipoteichoic acid treatment activated NFκB in WT- but not in TLR2-D mice. The NFκB-complex mainly consisted of p50 and p65 as depicted by
supershift assay (EMSA is representative of three animals per group).
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http://www.journal-inflammation.com/content/10/1/33Software (Applied Biosystems) using TaQman Gene ex-
pression Master Mix (part 4369016; Applied Biosystems)
with the following primers: TLR2 (Mm01213946_g1),
TNF-α (Mm00443258_m1), IL-1β (Mm99999061_mH)
and the house-keeping gene GAPDH (Mm99999915_g1).
All murine primers were measured using FAM TAMRA
chemistry and the relative standard curve method. At the
end of RT-qPCR cycle dissociation curve analysis was
performed to ascertain the amplification of a single PCR
product. Target gene expression was normalized to aninternal control (glyceraldehyde-3-phosphate dehydrogen-
ase, GAPDH) and relative quotient results were analyzed
with GraphPad Prism 5 (GraphPad Software, San Diego,
CA, USA).
Enzyme linked immunosorbent assay
Whole hearts were dispersed with an Ultra-Turrax, homog-
enized and incubated on ice for 5 min in 1 ml of enzyme
linked immunosorbent assay (ELISA) buffer containing
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Figure 2 Time course of pro-inflammatory cytokines in hearts of WT- and TLR2-D mice following LTA administration (15 mg/kg, i.p.).
A, B: RT-qPCR of TNF-α and IL-1β Both cytokines revealed a significant increase in WT-mice after 2 h (*p < 0.05; n = 6; mean ± SEM). C, D: ELISA
of TNF-α and IL-1β. LTA administration led to a significant increase in protein expression of both TNF-α and IL-1β in WT- but not TLR2-D mice
with a maximum at 4 h (*p < 0.05; n = 6; mean ± SEM).
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panol, 1 μl/ml) and protease inhibitors (Roche, Mannheim,
Germany). Samples were incubated on ice for 20 min, vor-
texed and centrifuged for 15 min at 4°C. TNF-α and IL-1β
protein levels were determined in the supernatant via
ELISA (R&D Systems, Minneapolis, MN, USA).Ribonuclease protection assay
Cytokine messenger RNA (mRNA) levels were analyzed
using a ribonuclease protection assay (RPA) for comparison
of specific stimulation of TLR2, -4 and −9 4 h after applica-
tion of the respective TLR ligand. Flash-frozen tissue
was homogenized and total RNA was extracted by the
guanidinium-thiocyanate method as described in [6].
The mRNA expression of TLR2, TLR4 and of pro-
inflammatory mediators (TNF-α, IL-1β, IL-6, and iNOS)
was determined with custom made template sets (BD
Biosciences, Heidelberg, Germany). Signals were quanti-
fied with AIDA software v3.5 (Raytest, Straubenhardt,
Germany) and normalized to the housekeeping gene
ribosomal protein L32.Multiplex cytokine assay
Blood was obtained from the abdominal aorta 0, 2, 4
and 6 h after stimulation with LTA using heparinized
syringes, centrifuged and the supernatant (serum) was
stored at −20°C. After thawing, samples were analyzed
immediately. Levels of TNF-α, IL-1β, IL-6 and IL-12
(Mouse cytokine multi-Plex for Luminex™ laser, BioSource
Europe, Nivelles, Belgium) were determined using the
microsphere array technique (Luminex Corporation, Austin,
TX, USA) as previously described [15].
Isolation, cell culture and incubation of cardiac myocytes
Excised hearts were prepared in Tyrode’s solution with
ethylene glycol tetraacetic acid (EGTA) instead of CaCl2
(in mM: 135 NaCl, 4 KCl, 1 MgCl2, 2 hydroxyethyl
piperazineethanesulfonic acid (HEPES), 2.6 EGTA, 10
glucose, and 1 mg/ml bovine serum albumin (BSA),
pH 7.4) and mounted in a Langendorff perfusion system.
Pressure was adjusted to 0.05 bar and the temperature
to 36°C. Hearts were then perfused with the preparation
solution for 5 min followed by a high-K+ solution for
5 min (in mM: 4 NaCl, 10 KCl, 130 K-glutamate, 1




























































Figure 3 Time course of serum cytokines in WT and TLR2-D mice after LTA stimulation (15 mg/kg i.p.). A-D: Multiplex cytokine assay of
TNF-α, IL-1β, IL-6 and IL-12. Peak protein levels of all cytokines were detected 2 h after stimulation in WT-mice. No increase was detected in
TLR2-D animals (*p < 0.05 vs. TLR2-D; n = 5; mean ± SEM).
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BSA; pH 7.4 (KOH)). Trypsin (1000 BAE units/40 ml;
Roche, Mannheim, Germany) and collagenase (type L,
25 mg in 40 ml, Sigma, St. Louis, MO, USA) were added
to the high-K+ solution and hearts were perfused for
8–10 min in trypsin and for another 10–13 min in
collagenase. Hearts were then sectioned into small
parts and transferred into Tyrode’s solution, with
1.8 mM CaCl2 in place of EGTA and supplemented
with trypsin-inhibitor 0.17 mg/ml (Sigma). The pieces
were disintegrated by stirring with glass rods, and the
solution was filtered and centrifuged. Cardiac myo-
cytes of both mouse strains were tested immediately
after isolation to determine baseline contractility. Treat-
ment groups were incubated in culture medium (CM)
consisting of Dulbecco’s modified Eagle medium, 5%
minimal essential medium, 10% fetal calf serum, 50 μg/ml
gentamicin (culture media from Gibco, New York,
NY, USA) both with and without LTA (10 μg/ml) [16]
from 1–8 h. Furthermore, the specific iNOS-inhibitor
S-methylisothiourea (SMT; 100 μM; Sigma Aldrich)
was added to the myocytes in culture one hour before
measurement to investigate NO dependency of cardiac
depression.Sarcomere shortening
Sarcomere shortening of isolated ventricular myocytes
was recorded via a video imaging system and SarcLen®
software (IonOptix Limited, Milton, MA, USA) according
to study design step C). The regular striation pattern of
sarcomeres in a field of interest was analyzed using fast
Fourier transformation (FFT). The video system was
mounted onto an inverted microscope (Zeiss Axiovert
135TV, Jena, Germany, lens Fluar 40x 1.3) equipped
with an experimental chamber perfused with Tyrode’s
solution (≈ 600 μl/min leading to an exchange rate of
three times per minute in the 200 μl volume of the
chamber) heated to 36°C. Sarcomere shortening was
monitored in Tyrode’s solution to avoid direct effects
of the incubation media on the contractile response.
Contractions were induced by bipolar external stimuli
(0.4 ms, 30 V, SD9, Grass, Quincy, MA, USA). Stimuli
were applied in pulse trains of 20 stimuli interrupted
by 30 s stimulation pauses. The stimulation protocol was:
0.5, 10, 1, 8, 2, 6, and 4 Hz. The five last shortening signals
of each train were averaged to obtain representative short-
ening frequency relationships. The resulting signal was
evaluated for the following parameters: amplitude of sarco-
mere shortening, maximal first derivative of sarcomere
TLR2

























































































































Figure 4 PRR and cytokine mRNA expression in hearts of WT mice 4 h after stimulation with different TLR ligands as detected by RPA.
B, C, D: LTA stimulation (15 mg/kg, i.p) resulted in a significant increase of mRNA expression of TLR2, TNF-α and IL-1β. A-F: LPS stimulation
(20 mg/kg, i.p.) led to a significant increase among all investigated parameters. B, E: CpG-ODN stimulation (1 nmol/g, i.p.) induced a significant
increase of TNF-α and TLR2 expression (Values are expressed as arbitrary units, AU; p < 0.05; n = 4; mean ± SEM).
Boehm et al. Journal of Inflammation 2013, 10:33 Page 6 of 13
http://www.journal-inflammation.com/content/10/1/33shortening, and re-lengthening. For the identification and
evaluation of staircases, trains of 20 original recordings of
sarcomere shortening of cardiomyocytes were averaged.
The peak values were fitted using a double exponential
function as previously published [17].
Hemodynamic measurements
Animals underwent hemodynamic measurement via pres-
sure-volume catheter 4 h after LTA stimulation according
to study design step D). After preparation of the right
carotid artery a 1.4 F pressure conductance catheter(SPR-839, Millar Instruments, Houston, TX, USA) was
inserted and advanced into the left ventricle. Data were
recorded with Chart 5.5.5 (AD Instruments, Spechbach,
Germany) and later analyzed with PVAN 3.6 (Millar
Instruments). Volume signals were received in arbitrary
relative volume unit numbers. Calibration of the conduct-
ance signal was performed in two steps: a) a 10 μl bolus of
a hypertonic (10%) saline solution was injected into the
external jugular vein to determine parallel conductance at
the end of baseline measurement and b) whole blood







Figure 5 (See legend on next page.)
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Figure 6 Hemodynamic parameters in WT- and LTA-treated mice. A-G: Cardiovascular function as measured with a pressure-volume catheter
4 h after LTA stimulation (15 or 30 mg/kg i.p.). LTA challenge did not influence hemodynamic parameters at this time point compared to control
(HR = heart rate, ESP = end-systolic pressure, SV = stroke volume, EF = ejection fraction, first derivative of pressure rise = dP/dtmax, first derivative
of pressure fall = dP/dtmin, CO = cardiac output; n = 6; mean ± SEM). H: Control recordings of arterial blood pressure (artBP) performed with a pressure
catheter 6 h after LTA stimulation (15, 30 or 50 mg/kg i.p.). No influence on blood pressure after LTA challenge was observed (systolic arterial blood
pressure (syst.); diastolic arterial blood pressure (diast.); n = 6; mean ± SEM).
(See figure on previous page.)
Figure 5 Sacomere shortening of isolated cardiomyocytes after incubation with LTA (10 μg/ml). A-D: Averaged original recordings of
sarcomere shortening from WT- and TLR2-D cardiomyocytes with LTA or in culture medium (CM) alone. After 30 s stimulation-pause cells were
stimulated at 1 Hz. The mean peak values (± SEM) of sarcomere shortenings were fitted by a double exponential function to give an impression
of the time course of the staircase. Lipoteichoic acid treatment reduced shortening amplitudes only in WT-cells (plots averages of n = 5).
E-G: Shortening-frequency plots of steady-state sarcomere shortening. Sarcomere shortening of WT- and TLR2-D cardiomyocytes was recorded within
60 min after isolation (Tyrode) or 6 h after incubation with LTA or in CM alone (E, F; * LTA vs. Tyrode, # LTA vs. CM). After 5 h of incubation with LTA
in CM one group was transferred to CM with LTA supplemented with the iNOS-inhibitor SMT (LTA + SMT) (G; * LTA vs.CM, # LTA vs. LTA + SMT; E-G:
n = 10–38 cells; mean ± SEM).
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a series of six cylinders, the conductance of each was
recorded, and a calibration curve was generated according
to the manufacturer’s protocol. The following parameters
were recorded: heart rate (HR); end systolic pressure (ESP);
stroke volume (SV), ejection fraction (EF); maximal first
derivative of pressure rise (dP/dtmax), maximal first deriva-
tive of pressure fall (dP/dtmin) and cardiac output (CO).
In an additional set of independent control experiments
hemodynamic parameters were recorded by a second in-
vestigator with a 1.4 F pressure catheter (Millar instru-
ments, Houston, TX, USA) instead of the pressure-volume
catheter. The following parameters were measured: HR;
systolic arterial pressure (SAP); diastolic arterial pressure
(DAP; not shown); left ventricular systolic pressure (LVSP;
not shown), left ventricular end-diastolic pressure (LVEDP;
not shown); dP/dtmax, dP/dtmin (not shown). Furthermore,
in this series of experiments LTA from Sigma-Aldrich was
applied (15, 30, 50 mg/kg) for 6 h.
Statistical analysis methods
All values are expressed as mean ± SEM. One-way ANOVA
analyses followed by Newman-Keuls-Tests post hoc
analysis were used to determine significant differences
using GraphPad Prism 5.0. Differences were considered to
be significant at p < 0.05.
Results
Clinical symptoms after LTA challenge
Following 4 h of LTA challenge, WT-mice developed
shock-like symptoms such as lethargy, nasal and ocular
discharge as well as piloerection. Severity of these symp-
toms appeared to be associated with the applied LTA
dosage. Toll like receptor 2-D mice did not show any
clinical signs of sickness. Lipopolysaccharide or CpG-ODN
challenge initiated signs of severe inflammation starting
2 h after stimulation [13].
Cardiac TLR2 expression
Lipoteichoic acid induced a significant up-regulation of
TLR2 mRNA in myocardial tissue after 2 h in compari-
son to baseline and to TLR2-D mice (Figure 1A). Peak
expression was detected 4 h after stimulation (≈7-fold
increase in WT). An apparent TLR2 increase in TLR2-D
mice (not significant) might be linked to the RT-qPCR
primer construct binding rudimentary parts of the C-
terminal promotor region for TLR2 according to the
manufacturer.
NFκB activation in myocardial tissue
The time course of myocardial NFκB-DNA binding activity
following LTA stimulation is depicted in Figure 1B. Lipo-
teichoic acid treatment led to robust time-dependent
binding activity of myocardial NFκB in WT-mice starting at1 h and lasting up to 4 h. In TLR2-D mice NFκB regulation
was not detectable. The NFκB-complex mainly consisted
of p50 and p65 as detected in the supershift assay.
Myocardial cytokine mRNA and protein expression
Lipoteichoic acid induced an increase of TNF-α and IL-1β
mRNA transcripts in hearts of WT-mice with a TNF-α
peak at 4 h and an IL-1β peak at 2 h after injection of LTA
(TNF-α: ≈ 14-fold and IL-1β: ≈ 22-fold in WT). In TLR2-D
animals this effect could not be detected (Figure 2A-B).
Respective protein expressions in the heart were mea-
sured by ELISA (Figure 2C-D). Lipoteichoic acid admin-
istration led to an increase in protein expression of both
TNF-α and IL-1β in WT-mice with a maximum at 4 h
(TNF-α ≈ 3-fold and IL-1β ≈ 8-fold compared to control),
which was not observed in TLR2-D animals.
Cytokine mRNA expression after stimulation with
different TLR-ligands was detected by RPA. At 4 h, LTA
stimulation resulted in an increase of mRNA expression
of TLR2, TNF-α and IL-1β (Figure 4), which was in accord-
ance with our results from RT-qPCR. Lipopolysaccharide
stimulation resulted in a significant increase of all
investigated parameters 4 h after application. CpG-ODN
challenge led to a significant increase of TNF-α and TLR2.
Serum cytokine levels
Multiplex cytokine assay revealed that LTA-treated WT
animals showed an increase of TNF-α, IL-1β and IL-12
serum levels 2 and 4 h after stimulation (Figure 3A, B, D).
Interleukin-6 however, was increased only 2 h after stimu-
lation (Figure 3C). In TLR2-D mice, LTA stimulation did
not induce any cytokine expression.
Influence of LTA on sarcomere shortening
Murine cardiomyocytes exhibit a characteristic frequency-
dependent shortening pattern after a stimulation rest. The
post-rest shortening is followed by a negative staircase at
low frequencies (Figure 5A-D) (< 6 Hz) and a positive
staircase at high frequencies (> 6 Hz; data not shown). This
contractility pattern was similar among cardiomyocytes
from both WT and TLR2-D mice (Figure 5A-D). Treat-
ment of cardiomyocytes with LTA (10 μg/ml) for more
than 4 h depressed both post-rest and steady-state short-
ening of WT but not TLR2-D cardiomyocytes (Figure 5C,
D). A detailed analysis exhibited a tendency to decreased
shortenings 3 h after the start of treatment reaching signifi-
cance at 4 h (data not shown).
Steady state shortening exhibits a biphasic shortening-
frequency relationship negative below 2 Hz and positive
above 2 Hz. At 2 Hz shortening was minimal (Figure 5E-G)
in both WT and TLR2-D cells. Lipoteichoic acid induced
a significant decrease of shortening amplitude in WT
cells at 0.5, 4 and 6 Hz as compared to culture medium
(CM) (Figure 5E). Lipoteichoic acid changed frequency-
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amplitude was depressed to a higher degree at low
frequencies than at high frequencies. At the highest
frequency (10 Hz = physiological heart rate of mice) LTA
did not depress the shortening amplitude. Steady-state
shortening of TLR2-D cells was insensitive to LTA
challenge (Figure 5F). The speed of sarcomere shortening
as well as re-lengthening showed the same frequency
relationship as the sarcomere shortening amplitude. In
WT-cells LTA suppressed both parameters significantly
(data not shown). To further elucidate a possible under-
lying mechanism we investigated the influence of iNOS
inhibition on LTA-dependent suppression of sarcomere
shortening (Figure 5G). Again, the steady-state shortening
amplitude was significantly reduced at 0.5, 1, 2, 4, 6 and
8 Hz. Addition of S-methylisothiourea (SMT, 100 μM)
applied during the last hour of LTA treatment reversed
the reduction of shortening completely (Figure 5G).
Hemodynamic function after LTA challenge
Measurements with a pressure-volume catheter were
performed 4 h after LTA stimulation because cytokine
protein expression peaked at this time point. These re-
cordings revealed that HR, ESP, SV, EF, dP/dtmax, dP/dtmin
and CO were not influenced after 4 h (Figure 6A-G). Even
doubling of the LTA dosage (30 mg/kg, i.p.) did not alter
cardiac function (Figure 6A-G). In a control experiment
performed with a pressure catheter by a second investiga-
tor 6 h after LTA administration (15, 30 or 50 mg/kg)
hemodynamic parameters were monitored. Interestingly,
here again LTA did not influence most of the recorded
hemodynamic parameters (SAP, DAP: Figure 6H; LVSP,
LVEDP, dP/dtmax, dP/dtmin: data not shown) with the
exception of HR, which was significantly elevated 6 h
after application of 50 mg/kg LTA (data not shown).
Discussion
This study shows the effects of highly purified LTA on
cardiac inflammation and hemodynamic parameters in vivo
for the first time. Lipoteichoic acid application induced an
inflammatory reaction in the heart, which was reflected in
an up-regulation of systemic cytokine levels. However,
hemodynamic parameters in vivo were not decreased by
LTA challenge. In contrast to these observations, in vitro
incubation of cardiac myocytes with LTA reduced sarco-
mere shortening in an NO-dependent manner. As LTA
induced clinical symptoms but hemodynamic changes
seemed to be moderate we compared LTA inflammatory
effects with those of TLR4 and TLR9 ligands.
The murine myocardium constitutively expresses TLR2
[9,18] but, so far, little is known about its role in septic
myocardial impairment. We stimulated TLR2 with its
specific ligand LTA [19], which led to a significant
up-regulation of TLR2 gene expression peaking after 4 h.These findings support the previous observation that
TLR2 up-regulation in the heart can also be induced by
heat inactivated S. aureus [9]. Hence, it can be speculated
that TLR2 induction plays an important role in long-lasting
inflammation. Similarly, TLR2 up-regulation has been re-
ported for other organs and under conditions considerably
different from ours [20,21].
Our study revealed robust activation of NFκB following
LTA stimulation in the heart, which ultimately resulted in
an increased release of TNF-α and IL-1β. This effect was
not observed in TLR2-D animals. Another TLR2 ligand,
peptidoglycan-associated lipoprotein, also increased TNF-α
expression in HL-1 cardiomyocytes in the study of Zhu
et al. [22]. In addition, in whole rat hearts mounted on a
Langendorff perfusion TNF-α levels increased after LTA
application [16].
In a fibroblast assay we demonstrated earlier that
the applied concentrations of LTA (15 mg/kg i.p.), LPS
(20 mg/kg i.p.) and CpG-ODN (1 nmol/g i.p.) are equipo-
tent with respect to TNF-activity induction [14]. These
equivalent concentrations of LPS, LTA and CpG-ODN
were applied in this experimental setting as well. Conse-
quently, all three stimuli significantly induced TNF-α
expression in the heart. Unlike TNF-α, other inflammatory
mediators were differentially regulated by the three TLR-
ligands. The strongest induction was caused by LPS, which
elevated levels of all tested mediators significantly. As LPS
and CpG-ODN have been shown to impair whole heart
contractility in vivo [23,24] and cardiomyocyte shortening
[13,25], we challenged isolated cardiomyocytes with
10 μg/ml of LTA and recorded sarcomere shortenings.
This in vitro applied concentration of LTA is well in the
range of earlier investigations. Grandel et al. demonstrated
cardiac depression in an ex vivo Langendorff perfusion at
2 and 10 μg/ml of LTA [16]. Furthermore, 10 μg/ml of
LTA has been shown to markedly inhibit neutrophil
chemotaxis [26]. In the present study LTA challenge in-
duced a significant depression of cardiomyocyte sarcomere
shortening at stimulation frequencies ≤ 8 Hz, which was
not observed in TLR2-D cells. This is in agreement with
a previous study by et Zhu al., in which peptidoglycan-
associated lipoprotein diminished both calcium transients
and sarcomere shortenings in cardiomyocytes in a TLR2-
and MyD88-dependent manner at 1 Hz [22]. It should be
noted that a stimulation frequency of 1 Hz corresponds to
a heart frequency of 60 bpm and hence, is not relevant
in vivo in mice. To simulate in vivo heart frequencies in
mice isolated cardiomyocytes were stimulated with fre-
quencies up to 10 Hz in this experiment. Interestingly, the
extent of depression weakened at stimulation frequencies
above 6 Hz and was completely absent at 10 Hz, i.e. LTA
did not reduce sarcomere shortening at the physiological
heart rate of mice. In contrast it has been shown earlier
that LPS and CpG-ODN diminished sarcomere shortening
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[13,25]. We found depression of sarcomere shortening
occurred after 4 h of LTA incubation, which paralleled
the peak TNF-α protein levels in vivo. This is supported
further by the observation of Grandel et al. that LTA
induced whole heart cardiac depression could be prevented
by application of a neutralizing TNF-α antibody [16]. In
addition, it has been demonstrated that TNF-α initiates
excessive NO release either via cardiac endothelial nitric-
oxide synthase (eNOS) or via iNOS [7]. In our in vitro
experiments the application of the highly selective iNOS-
inhibitor SMT abolished the suppression of sarcomere
shortening indicating an NO-dependency. Nitrous oxide-
dependency of depressed sarcomere shortening was
observed earlier after LPS and CpG-ODN challenge of
isolated cardiomyocytes [13,25].
To further elucidate the influence of LTA stimulation
on cardiac function in vivo we measured hemodynamic
parameters with a pressure-volume catheter. Surprisingly,
no alteration of myocardial function was observed after
challenge with LTA (15 mg/kg i.p.) in vivo. Even after
increasing the dosage to 30 mg/kg, LTA did not affect
contractile function. To further confirm these results, a
second experiment was conducted using a pressure cath-
eter and commercially available LTA charges. Again LTA
did not influence hemodynamic parameters. Therefore, the
LTA dosage as well as the exposure time was increased to
50 mg/kg and 6 h. Unexpectedly, HR increased under
these conditions.
The surprising difference between the in vitro and
in vivo effects on cardiac activity might be explained by
differences in the concentration of LTA in both situations.
However, 10 μg/ml in vitro equals 10 mg/kg, which is in
the range of the in vivo dosage applied in this study. This
LTA dosage was much higher than the one used by Finney
et al. showing changes in leukocyte adhesion (50 μg/kg
estimated from 100 μg/rat) [27] and the 4 mg/kg used
by Zhao et al. [28]. Others have applied between
10–1000 μg/mouse LTA, thereby inducing a distinct
microRNA pattern [29]. Thus, the dosage of LTA applied
here was in the range of the highest doses found in litera-
ture, provoked cardiac inflammation and should have also
been able to cause consecutive depressed cardiac function.
However, this latter effect was not observed in vivo.
To explain this surprising finding the experiments on
isolated cardiomyocytes should be taken into account in
detail. Isolated cardiomyocytes were incubated with LTA
in culture dishes and attachment of LTA to polystyrene has
been shown to augment its immunostimulatory potency,
which could be abrogated in the presence of plasma [30].
However, in our experiments cardiomyocytes were in-
cubated with LTA in the presence of 10% fetal calf serum,
which may share some components with plasma. Therefore,
this surface-dependent augmentation of LTA effectsmay have contributed to, but cannot fully explain the
differences seen between in vitro and in vivo experiments.
Furthermore, in vitro we found depression of sarcomere
shortening only at stimulation frequencies ≤ 8 Hz, which
is clearly below the physiological heart rate of mice. In
earlier experiments using heat-inactivated S. aureus as a
stimulus cardiac contractility decreased, as measured in a
Langendorff preparation [9]. But stimulation frequency
was also below the physiological range in these experi-
ments. In addition, the immunological potency of heat-
inactivated S. aureus LTA may be higher than that of
purified LTA, as LTA lacking lipoproteins has been shown
to be less potent than WT LTA due to different signaling
mechanisms [31].
Reduced sarcomere shortening in vitro could be antago-
nized by an iNOS inhibitor (SMT). In contrast, increased
iNOS expression after LTA treatment in the heart in vivo
could not be detected here nor in rat heart by others [16].
But, significant iNOS elevation has been reported due to
the simultaneous application of LTA and peptidoglycan
(PGN) [32]. Recently PGN and its subcomponent muramyl
dipeptide (MDP) have been shown to signal only via NOD
receptors [33,34] indicating a more complex synergistic
mechanism. Furthermore, some inflammatory responses
initially associated with specific TLR2-ligand-derived signal-
ing have been attributed to LPS contamination later [35].
Vascular contractility is known to contribute decisively
to maintenance of arterial blood pressure. Thus, the
sensitivity of the arterial wall to LTA will influence the
blood pressure in the situation of a TLR2-dependent
inflammation. Recently it has been shown that LTA appli-
cation to isolated blood vessels can even improve vascular
contractility [11]. This effect may support the stability of
SABP observed here.
Conclusions
Toll-like receptor 2-stimulation in vivo with LTA alone
induced only a moderate inflammatory response compared
to stimulation via TLR4 or TLR9. One might speculate that
Gram-positive bacteria initiate innate immunity to a greater
extent when diverse PAMPS and antigens of the bacterium
are presented and thus, the numerous receptor-signaling
networks of innate immunity are induced in close cooper-
ation. LTA alone displays moderate pro-inflammatory
properties via TLR2 alone, LTA and PGN show a strong
synergistic effect via TLR2 and NOD2 [33] and whole
bacteria might additionally stimulate TLR9 via their
bacterial DNA [13]. These findings indicate that purified
LTA contributes to cardiac inflammation, yet does not
significantly influence cardiac function. Given the intricacy
of innate immunity, the role of LTA cannot yet be resolved.
Future detailed studies of single TLR-dependent immune
responses are required to demonstrate the extent to which
LTA is relevant in the clinical context.
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